Management of patients with chronic stable angina at low risk for serious cardiac events

American Journal of Cardiology

Volumn 79, Issue 12 B, 1997, Pages 24-30

  Thadani, Udho ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; DILTIAZEM; ESTROGEN; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRIC ACID DERIVATIVE; VERAPAMIL;

ANGINA PECTORIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK MANAGEMENT; SMOKING; SMOKING CESSATION; SUPRAVENTRICULAR TACHYCARDIA;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; CORONARY DISEASE; FEMALE; HUMANS;

EID: 0030793216     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00382-2     Document Type: Conference Paper

References (47)

1. Thadani U, Chohan A. Chronic stable angina pectoris. Strategies for effective drug therapy. Postgrad Med. 98:1995;175-188.
2. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin. 9:1991;73-87.
3. Mehta JL. Endothelium, coronary vasodilation, and organic nitrates. Am Heart J. 129:1995;382-391.
4. Taylor CR, Hodge EM, White DA. Circadian rhythm of angina: similarity to circadian rhythms of myocardial infarction, ischemic ST segment depression, and sudden cardiac death. Am Heart J. 118:1989;1098-1099.
5. Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, Mock MB, Pettinger M, Robertson TL. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation. 82:1990;1629-1646.
6. Chaitman BR. What has happened to risk stratification with noninvasive testing. ACC Current Journal Review. Sept/Oct:1996;33-35.
7. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 106:1987;793-800.
8. Weiner DA, Ryan TJ, McCabe CH, Chaitman BR, Sheffield LT, Ferguson JG, Fisher LD, Tristani F. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol. 3:1984;772-779.
9. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation. 86:1990;121-130.
10. Klein J, Chao SY, Berman DS, Rozanski A. Is 'silent' myocardial ischemia really as severe as symptomatic ischemia? The analytical effect of patient selection biases. Circulation. 89:1994;1958-1966.
11. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild-to-moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 153:1993;578-581.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin Survival Group Study (4S). Lancet. 344:1994;1383.
13. Hermanson B, Omenn GS, Kronmal RA, Gersch BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS Registry. N Engl J Med. 319:1988;1365.
14. Effects of estrogen or estrogen/progestin on heart disease risk factors in post menopausal women. JAMA. 273:1995;199.
15. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
16. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen X, Ömblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 340:1992;1421-1425.
17. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
18. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
19. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinipril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 94:1996;258-265.
20. Wang XL, Tam C, McCredie RM, Wilcken DE. Determinants of severity of coronary artery disease in Australian men and women. Circulation. 89:1994;1974.
21. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Yasue H. Cigarette smoke extract contracts isolated porcine coronary arteries by superoxide anion-mediated degradation of EDRF. Am J Physiol. 266:1994;H874-H880.
22. Abrams J. Therapy of angina pectoris with long-acting nitrates: Which agent and when? Can J Cardiol. 12:((suppl)):1996;9C-16C.
23. Haber HL, Simek CL, Bergin JD, Sadun A, Gimple LW, Powers ER, Feldman MD. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. J Am Coll Cardiol. 122:1993;251-257.
24. Feelisch M, Brands F, Kelm M. Human endothelial cells bioactivate organic nitrates to nitric oxide: implications for the reinforcement of endothelial defense mechanisms. Eur J Clin Invest. 25:1995;737-745.
25. Harrison DG, Kurz MA, Quillen JE, Mugge A. Normal and pathophysiologic considerations of vascular tone and their relevance to nitrate therapy. Circulation. 87:1993;1461-1467.
26. Yeung AC, Vekshtein VI, Drantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 325:1991;1551-1556.
27. Gage JE, Jess DM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina: reversibility by nitroglycerin. Circulation. 73:1986;865-876.
28. Fallen EL, Nahmia SC, Scheffel X, Coates G, Beanlands R, Garnett ES. Redistribution of myocardial blood flow with topic nitroglycerin in patient with coronary arterial disease. Circulation. 91:1995;1381-1388.
29. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol. 27:1996;658-663.
30. Duncker DJ, Mizrahi J, Bache RJ. Nitrovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries. J Cardiovasc Pharmacol. 25:1995;823-832.
31. Thadani U, Lipicky RJ. Short- and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 8:1994;611-623.
32. Bennett D, Daviesa A, Davis A. Sustained anti-anginal action of triglyceryl trinitrate cream. Br J Clin Pharmacol. 15:1983;173-180.
33. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther. 8:1994;625-633.
34. Thadani U, Maranda CR, Amsterdam E, Spaccavento L, Friedman RG, Chernoff R, Zellner S, Gorwit J, Hinderaker PH. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med. 120:1994;353-359.
35. Abshagen U, Betzien G, Endele R, Kaufmann B. Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol. 20:1981;269-275.
36. Parker JO, Farrell B, Lahey KA, Moe G. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 316:1987;1440-1444.
37. Isordil Titradose prescribing information from Wyeth-Ayerst.
38. Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, Watts LE, Garutti RJ, Ferraresi R, Casareto R. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 72:1993;1249-1256.
39. Opie LH, Sonnenblick EH, Frishman WH, Thadani U. β -blocking agents. Opie LH. Drugs for the Heart. 4th ed. 1995;50-82 WB Saunders, Philadelphia.
40. Opie LH, Frishman WH, Thadani U. Calcium channel antagonists (calcium entry blockers). Opie LH. Drugs for the Heart. 4th ed. 1995;50-82 WB Saunders, Philadelphia.
41. Singh N, Langer A. Current status of silent myocardial ischemia. Can J Cardiol. 11:1995;286-289.
42. . Exercise electrocardiogram and coronary heart disease mortality in the multiple risk factor intervention trial. Am J Cardiol. 55:1985;16-23.
43. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, Miller E, Marks RG, Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation. 90:1994;762-776.
44. Egstrup K. Silent ischemia and β -blockade. Circulation. 84:((Suppl VI)):1991;VI-84-VI-92.
45. Pepine CJ, Abrams J, Marks RG, Morris JJ, Scheidt SS, Handberg E. Characteristics of a contemporary population with angina pectoris. TIDES investigators. Am J Cardiol. 74:1994;226-231.
46. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: The Society of Thoracic Surgeons National Database Experience. Ann Thorac Surg. 57:1994;12.
47. Rahimtoola SH, Bennett AJ, Grunkemeier GL, Block P, Starr A. Survival at 15-18 years after coronary bypass surgery for angina in women. Circulation. 88:1993;II71-II78.